Johnson Craig A 4

What Happened Craig A. Johnson, a director of Heron Therapeutics, was granted 53,960 restricted stock units (reported as an acquisition, code A) on January 30, 2026. The Form 4 lists the acquisition price as $0.00 (total $0) because these are RSUs — each unit is a contingent right to one share of common stock that will convert on vesting.

Key Details

• Transaction date: 2026-01-30 (Grant/Award, transaction code A).
• Filing date / Accession: Form 4 filed 2026-02-03 (within the two-business-day filing window).
• Shares granted: 53,960 RSUs; reported price $0.00 (total $0) on the Form 4.
• Vesting: RSUs vest in full on 2027-01-30 (per footnote).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote: Each RSU is a contingent right to receive one share of common stock upon vesting.

Context RSU grants are a form of compensation — the award itself is not a market purchase or sale and does not represent immediate cash flow or trading by the insider. The economic value of the grant will depend on Heron’s share price when the RSUs vest (and any applicable tax withholding). This filing appears to be a routine, timely disclosure of a director compensation award.